Recently, a number of screening methods have been developed to identify small molecules that might mimic the biological effects of hematopoietic growth factors. The potential advantages of small molecule mimics include lack of immunogenicity, fewer drug side-effects, and nonparenteral routes of administration. Small molecules might also be less expensive to produce. Disadvantages include shorter half-life compared to larger proteins and differences in potency.
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The theoretical basis to attempt to design or screen for small molecule mimics of hematopoietic growth factors lies in multiple studies demonstrating that several types of molecules not related to growth factors can dimerize growth factor receptor subunits and induce signal transduction, thereby mimicking the biological effects of hematopoietic growth factors. Duplication of growth factor binding sites in a single molecule can initiate engagement of two receptor molecules and initiate signaling (as shown for erythropoietin (EPO)), as can the binding of bivalent monoclonal antibodies against receptor subunits (many examples). Similarly, mutations in the receptors themselves (EPO, thrombopoietin (TPO)) can initiate dimerization and cellular activation. Exogenous molecules such as the gp55 of the Friend leukemia virus can naturally dimerize the EPO receptor and lead to signal transduction. These results suggest that small molecule mimetics may be designed which can initiate signal transduction and demonstrate similar biological activity as the native growth factor.
One approach to identify mimetics is through phage display. In this system, oligonucleotide cassettes containing nucleotide substitutions encoding random peptide sequences are introduced into phage and the encoded altered proteins displayed on the phage surface. These altered phage are then incubated in a plate that contains an adherent growth factor receptor, such as the EPO or TPO receptors. If the altered phage coat protein has acquired some affinity for binding to the cytokine receptor, that phage will be preferentially captured. The other phage that encode peptides with no binding affinity will not be captured. After several rounds of selection, a population of phage highly enriched for binding to the target receptor is obtained, eluted from the plate, and the encoding DNA sequenced.
When this technique was used for screening for peptides that bind to the EPO receptor multiple phage were obtained, and when sequenced the encoded peptides were found to contain several conserved amino acids thereby allowing for the identification of a consensus sequence for receptor binding. Using the consensus sequence with additional changes another round of selection was performed, and a group of peptides with higher binding affinity were identified. The specificity of binding was confirmed by eluting the phage with increasing concentrations of EPO. In this way high affinity EPO receptor binding peptides were identified, and some of these molecules displayed EPO-like activity in vitro and in vivo.
One of these mimetic peptides was termed EMP-1, which was capable of binding and activating the EPO receptor. 1 While this molecule worked at a relatively low affinity (its potency was several logs less than EPO on a molar basis), it nevertheless engendered optimism that a small molecule mimetic might work in vivo. However, its mechanism of action was uncertain. When this peptide was crystallized in the context of the EPO receptor, it was demonstrated that two molecules of the peptide spontaneously dimerized, leading to receptor dimerization and, subsequently, signal transduction. 2 Because dimerization seemed to be critical for driving stimulation of the EPO receptor, the peptide was then intentionally dimerized by rational peptide construction, leading to a 10-fold improvement in its ability to bind to the EPO receptor and a 10-fold improvement in its ability to support cell proliferation. 3 When a similar approach was used to identify potential TPO mimetics, peptides were obtained that displayed a potency similar to the native growth factor. 4 With successive screens, binding affinities improved from 20 m to 60 nm. Similar to EPO, the dimerized peptide molecules demonstrated higher affinities. In vivo potency of these TPO mimetics has been demonstrated following their modification with polyethylene glycol (PEG). Injection of 2 g/kg resulted in doubling of the platelet count, and 10 g/kg tripled or quadrupled the count. The effects in monkeys were not quite as impressive and a much higher dose was required to double the platelet count, but subsequent studies have shown the peptide mimetic to protect animals from severe thrombocytopenia following chemotherapy.
A second strategy to identify mimetic molecules is the high throughput-screening assay. In this approach to small molecule mimetic recognition, a cell line is engineered to respond to a cytokine-induced signaling event with a luciferase reporter gene, which is then used to screen (usually) organic compounds for those that might mimic cytokine receptor stimulation. While fewer compounds can be screened efficiently using this technique than for phage display, a wider variety of compounds (ie, other than peptides) can be tested and there is reassurance that any positive in the assay is indicative of a functional (not just binding) response. With the phage display screening method, molecules are selected based only on binding affinity, not on ability to initiate receptor activation. This strategy has been used to screen for mimetics to the murine G-CSF receptor. Molecules were identified which could stimulate the neutrophil count in mice, but there was no activity on the human G-CSF receptor. Further studies are underway using the human G-CSF receptor as a target.
Based on the apparent requirement for small molecule dimerization, and much other data, the current working model of cytokine receptor activation is that cytokine receptor activation is dependent on ligand-induced dimerization or the generation of higher order multimers. However, this model presents a conundrum; given the small number of hematopoietic growth factor receptors on a cell (in most systems Ͻ500 per cell), the kinetics of receptor dimerization would be very unfavorable if ligand must bring together two spatially separated receptor subunits for every signaling event. It could thus be reasoned that preformed dimers of cytokine receptors must preexist, in an inactive conformation, requiring that incoming ligand only alter receptor conformation to initiate signaling. However, experimental proof for this concept was not quickly forthcoming. The study of interactions of EPOmimetic peptides and their cognate receptor has recently provided that proof.
About 4 years ago a crystal structure of EMP1 with the EPO receptor was solved. 2 In the crystal structure, the peptide mimetic binds to four of the six loops of the EPO receptor to which EPO normally binds, indicating that the mechanism of receptor engagement by mimetic peptides is physiologic and that a reduced area of receptor-ligand contact is also why peptide potency is less than that of the native hormone. A molecule that engaged all six loops of the receptor might be equipotent to the native ligand, an obvious target for future attempts at rational design. But far greater insights into cytokine receptor signaling were derived when one compared the structure of an EPO receptor dimer that formed in the presence of EPO or the mimetic peptide vs that of an EPO receptor dimer devoid of peptide or native hormone; the distance between the carboxyl terminae of EPO receptors is about 73 angstroms in receptor dimers devoid of ligand, but is about 40 angstroms closer together when the receptor is loaded with peptide. Thus, it appears that the EPO mimetic peptide, and by extrapolation EPO itself, brings the cytoplasmic domains of the receptor subunits together, leading to signaling.
Based on a promising start, it is likely that there will be a role for these molecules or their derivatives in the treatment of leukemia and other hematopoietic disorders. In addition to their potential for reduced costs and ease of administration, several other advantages for small molecule mimetics of cytokines arise. For example, if immunogenicity of TPO or other cytokines becomes a major issue, it has already been shown that small TPO peptides are not immunogenic in animal models. Another possibility is that small molecules will provide a convenient approach to the design of cytokine antagonists; many peptides have already been shown to display high binding affinity yet no biological activity due to the inability to dimerize or to bind two receptor subunits simultaneously. States of high TPO production, such as seen in several cases of familial thrombocytosis, might represent a testing ground for such strategies. Moreover, small molecules will continue to serve as outstanding ways to interrogate the receptor/cytokine interaction to provide important new insights into the molecular architecture that underlies the initiation of signal transduction. Thus, further studies of the interactions of the native growth factors with their receptors will almost certainly lead to the development of compounds more closely mimic the native biological activities, or provide innovative ways to block their interactions.
